Clinical trials: Hematologic Neoplasm
Cancer, Multiple Myeloma
Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study
The goal of this study is to evaluate the safety of melphalan and autologous PBSCT (peripheral blood stem cell transplantation - stem cells that come from your own body) in combination with bortezomib, a new FDA approved drug…
- Trial name
- NCT00793650
- Testing
- Bortezomib, Melphalan, Autologous PBSC Transplant
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Emory University
Diamond Blackfan Anemia, Dyskeratosis Congenita
Cancer in Inherited Bone Marrow Failure Syndromes
Background: A prospective cohort of Inherited Bone Marrow Failure Syndrome (IBMFS) will provide new information regarding cancer rates and types in these disorders.
- Conditions
- Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome
- Trial name
- NCT00027274
- Where
- 2 sites in United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (SLL)
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT06849713
- Testing
- Zanubrutinib, Sonrotoclax, Obinutuzumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Plasma Cell Myeloma
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
This phase II trial studies the effect of pembrolizumab in treating patients with multiple myeloma that is growing, spreading, or getting worse (progressing) on chimeric antigen receptor (CAR)-T cell therapy.
- Trial name
- NCT05204160
- Testing
- Pembrolizumab
- Where
- United States
- Sponsor
- Emory University
Acute Promyelocytic Leukemia, Relapse
ASCT for Relapsed APL After Molecular Remission
For relapsed acute promyelocytic leukemia after all-trans retinoic acid (ATRA) and arsenic treatment, remission can be achieved by chemotherapy with ATRA and/or arsenic and addition of mylotarg.
- Trial name
- NCT00907582
- Testing
- autologous hematopoietic cell transplantation
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia (AML)
Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML
This phase Ⅰ study of Donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess safety and pharmacokinetics in patients with Relapsed AML.
- Trial name
- NCT04402723
- Testing
- Donafenib
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Haematologic Disease
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation
For several decades, allogeneic hematopoietic stem cell trans-plantation (allo-HSCT) has remained an important strategy in the management of patients with high-risk hematological malignancies.
- Trial name
- CTL-DP 01 (NCT04180059)
- Testing
- CTL 19
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma
Cyclin D1 as a Prognostic Factor in Multiple Myeloma and Its Association With the Immunological Prognostic Factor PDL1 and Clinical and Biochemical Lab Tests
Multiple myeloma (MM) is the most common bone marrow malignancy of terminally differentiated plasma cells. It accounts for about 1% of all malignant diseases and 10% of haematological malignancies and takes the second place after…
- Trial name
- NCT05995808
- Testing
- Bone marow biopsy and aspiration, biochemical and heamatological tests
- Volunteers
- 30 people
- Sponsor
- Sohag University
Hematopoietic Neoplasm, Malignant Solid Neoplasm
Wearable Data for Personalized Prognostication in Cancer: A Registry Protocol
This study receives physiological and lifestyle-related data from mobile phones to create an institutional database.
- Conditions
- Hematopoietic Neoplasm, Malignant Solid Neoplasm, Lymphatic System Neoplasm, Hematopoietic and Lymphatic System Neoplasm
- Trial name
- NCT07691008
- Testing
- Non-Interventional Study
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Adult Double Unit Cord Blood Transplant
Double Unit Cord Blood Transplant in Hematologic Malignancies.
The efficacy and safety of non-myeloablative and myeloablative preconditioning followed by dual-unit umbilical cord blood transplantation from unrelated donors in adult patients with malignant hematologic diseases eligible for…
- Trial name
- NCT06712108
- Testing
- tranplant
- Where
- 6 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Seoul National University Hospital
Breast Cancer, Leukemia
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006225
- Testing
- filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin
- Where
- United States
- Sponsor
- Northwestern University
Multiple Myeloma
A Study of VLX1570 and Dexamethasone in Myeloma Patients
This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02372240
- Testing
- VLX1570 and dexamethasone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vivolux AB
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Relapsed or Refractory Multiple Myeloma (RRMM)
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - GPRC5D CAR-T cell therapy.
- Trial name
- NCT07003568
- Testing
- Dual-targeting BCMA-GPRC5D CAR-T cell infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
Myelogenous Leukemia, Acute
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in patients with acute myelogenous leukemia.
- Trial name
- NCT01641250
- Testing
- RO5429083, cytarabine
- Where
- 8 sites in France, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Leukemia
S9031-S9333-S0112-S0301-A Biomarkers Associated With Response to Cytarabine in Samples From Older Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer treated with cytarabine in the laboratory may help doctors learn more about the effects of cytarabine on cells.
- Trial name
- NCT01338974
- Testing
- gene expression analysis, proteomic profiling, flow cytometry
- Volunteers
- 290 people
- Sponsor
- SWOG Cancer Research Network
Acute Myeloid Leukemia, Myelodysplastic Syndrome
NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases
This is a phase II multi-institutional therapeutic study of NK-cell based nonmyeloablative haploidentical transplantation for the treatment of high-risk acute myeloid diseases. Enrollment will use a two-stage design.
- Trial name
- NCT01370213
- Testing
- Preparative Regimen, NK Cells, Interleukin-2
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
This research study is studying a cancer vaccine called Dendritic Cell/MM Fusion vaccine (DC/MM vaccine) in combination with nivolumab, as a possible treatment for multiple myeloma (MM).
- Trial name
- NCT03782064
- Testing
- Nivolumab, DC/myeloma fusions/GM-CSF
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Beth Israel Deaconess Medical Center
Leukemia
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01169363
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Multiple Myeloma
EMMA-1 (Erbitux for Multiple Myeloma)
EMMA-1 is an open-label, non-randomized, two-stage phase II study. Patients with refractory multiple myeloma stage II or III or relapsed disease after at least one line of treatment will receive Cetuximab+/-Dexamethasone.
- Trial name
- EMMA-1 (NCT00368121)
- Testing
- Cetuximab +/- Dexamethasone
- Where
- 3 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Prof. Dr. Andreas Engert